Kingsview Wealth Management’s Gilead Sciences GILD Stock Holding History

Kingsview Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,000	Closed	-$3K	–	930
2021 Q2	$3K	Buy	+2,000	New	+$134K	﹤0.01%	873
2020 Q2	–	Sell	-5,100	Closed	-$1K	–	628
2020 Q1	$1K	Buy	+5,100	New	+$352K	﹤0.01%	491
2018 Q4	–	Sell	-800	Closed	-$1K	–	400
2018 Q3	$1K	Buy	+800	New	+$60.4K	﹤0.01%	390
2018 Q2	–	Sell	-900	Closed	-$4K	–	393
2018 Q1	$4K	Buy	+900	New	+$71.5K	﹤0.01%	326
2017 Q3	–	Sell	-1,300	Closed	-$3K	–	382
2017 Q2	$3K	Buy	1,300 +1,000	+333%	+$66.5K	﹤0.01%	304
2017 Q1	$1K	Buy	+300	New	+$21.1K	﹤0.01%	286

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kingsview Wealth Management's GILD Position: Q1 2026 in Review

Kingsview Wealth Management reduced its Gilead Sciences (GILD) stake by 4.6% in Q1 2026, selling an estimated $105K and leaving 15,711 shares worth $2.19M. The position accounts for 0.03% of the portfolio, ranked #491.

Kingsview Wealth Management first reported a position in GILD in Q1 2017 and has held it in 30 quarters since. The position peaked at $4.85M in Q1 2025. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Kingsview Wealth Management held 15,711 shares of Gilead Sciences worth $2.19M as of Q1 2026.
Kingsview Wealth Management sold 752 Gilead Sciences shares in Q1 2026, an estimated $105K.
Gilead Sciences made up 0.03% of Kingsview Wealth Management's portfolio in Q1 2026, its #491 holding.
Kingsview Wealth Management first reported a position in Gilead Sciences in Q1 2017 and has held it in 30 quarters since.
Kingsview Wealth Management's Gilead Sciences position peaked at $4.85M in Q1 2025.
2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.